UNSPSC 51333508: Preclamol

This classification denotes an antipsychotic agent with the molecular formula C14H21NO, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 9V2O6CRQ6Z, chemically known as 3-[(3S)-1-propylpiperidin-3-yl]phenol but generally known as preclamol, which bears US NIH Compound Identifier 5311189. Most nations schedule preclamol under HS 29333999 and SITC 51574. As of Q4 2014, PRECLAMOL remains the US FDA Preferred Term for this commodity. Preclamol bears US NLM identifiers UMLS ID C0068168 and NCI Concept Code C82251.

SMILES: CCCN1CCCC(C1)C2=CC(=CC=C2)O.

UNSPSC 51333508 Preclamol is a Commodity code under which state and local governments procure pharmaceutical products, specifically naloxone and drug deactivation systems, generic pharmaceuticals, and over-the-counter medications distributed through authorized wholesalers and direct-to-manufacturer channels. Recent solicitations show state health agencies and county public health bodies buying these products to support community health initiatives, overdose response programs, and pharmacy benefit management across multiple jurisdictions through cooperative purchasing arrangements and standalone procurements.

The issuing bodies include Seminole County, Florida (a county health department), the Texas Health and Human Services Commission (a state agency), and the Minnesota Multistate Cooperative Purchasing Alliance (a multi-state cooperative vehicle administered by the Minnesota Department of Administration). Geographic activity spans Florida, Texas, Minnesota, and Oregon, with the cooperative purchasing structure extending reach across multiple states. Representative recent opportunities include Seminole County's IFB 60459723LAS (posted June 30, 2026, due July 26, 2023) soliciting 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries; the Texas Health and Human Services Commission's RFI HHS0017013 (posted April 3, 2026, due April 3, 2026) seeking vendor capabilities for direct-to-manufacturer prescription programs; and MMCAP's RFP S1070000015802 (posted January 20, 2026, due March 26, 2026) establishing multiple contracts for generic multi-source pharmaceuticals and OTC products through three authorized wholesalers (AmerisourceBergen Drug Corporation/Cencora, Cardinal Health, and Morris & Dickson), with contract effectiveness July 1, 2026. Vendors must comply with Drug Supply Chain Security Act requirements, current Good Manufacturing Practices certification, and FDA standards; maintain specified insurance coverage; and accept administrative fees (3 percent in the MMCAP vehicle) and performance penalties ranging from $200 to $1,500 per violation.